Joel Greenblatt's CAI Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 744,426 shares of Caris Life Sciences, Inc. (CAI) worth $13.31 M, representing 0.04% of the portfolio. First purchased in 2025-Q3, this short-term holding has been held for 3 quarters.
Based on 13F filings, Joel Greenblatt has maintained this position in CAI for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 677,240 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Caris Life Sciences (CAI) Holding Value Over Time
Track share changes against reported price movement
Quarterly Caris Life Sciences (CAI) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +677,240 | Add 1008.01% | 744,426 | $17.88 |
| Q4 2025 | +33,983 | Add 102.35% | 67,186 | $26.98 |
| Q3 2025 | +33,203 | New Buy | 33,203 | $30.25 |
Joel Greenblatt's Caris Life Sciences Investment FAQs
Joel Greenblatt first purchased Caris Life Sciences, Inc. (CAI) in Q3 2025, acquiring 33,203 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Caris Life Sciences, Inc. (CAI) for 3 quarters since Q3 2025.
Joel Greenblatt's largest addition to Caris Life Sciences, Inc. (CAI) was in Q1 2026, adding 744,426 shares worth $13.31 M.
According to the latest 13F filing for Q1 2026, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 744,426 shares of Caris Life Sciences, Inc. (CAI), valued at approximately $13.31 M.
As of the Q1 2026 filing, Caris Life Sciences, Inc. (CAI) represents approximately 0.04% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in Caris Life Sciences, Inc. (CAI) was 744,426 shares, as reported at the end of Q1 2026.